Objectives: To evaluate high-dose barbiturates as a second-tier therapy for pediatric refractory intracranial hypertension complicating severe traumatic brain injury. Design: This is a ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

Hypertension (HTN) increases the risk of development ... These may be used in CHF patients with refractory HTN. In patients with HF with reduced ejection fraction, HTN is treated differently ...

Adequate Sleep Significantly Reduces the Risk of Hypertension in Adolescents Nov. 11, 2024 — Adolescents who meet the recommended guidelines of nine to 11 hours of sleep per day were shown to ...

The following is a summary of “Hypertensive load predicts recovery of renal function for patients undergoing ...

Blood pressure medications are usually taken for life. However, some people can stop taking them by addressing those underlying causes of high blood pressure (hypertension) that can be changed, such ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

Nasdaq’s determination is based on the Company meeting all other applicable requirements for listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s ...

Service specifications are important in clearly defining the standards of care expected from organisations funded by NHS England to provide specialised care. The specifications have been developed by ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.